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Abstract
Background: Immune reconstitution inflammatory syndrome associated with dermatophytoses (tinea-IRIS) may
cause considerable morbidity. Yet, it has been scarcely reported and is rarely considered in the differential diagnosis
of HIV associated cutaneous lesions in Africa. If identified, it responds well to antifungals combined with steroids.
We present two cases of suspected tinea-immune reconstitution inflammatory syndrome from a large HIV clinic in
rural Tanzania.
Cases presentation: A first case was a 33 years-old female newly diagnosed HIV patient with CD4 count of 4 cells/
μL (0 %), normal complete blood count, liver and renal function tests was started on co-formulated tenofovir/
emtricitabine/efavirenz and prophylactic cotrimoxazole. Two weeks later she presented with exaggerated
inflammatory hyperpigmented skin plaques with central desquamation, active borders and scratch lesions on the
face, trunk and lower limbs. Tinea-IRIS was suspected and fluconazole (150 mg daily) and prednisolone (1 mg/Kg/
day tapered down after 1 week) were given. Her symptoms subsided completely after 8 weeks of treatment, and
her next CD4 counts had increased to 134 cells/μL (11 %). The second case was a 35 years-old female newly
diagnosed with HIV. She had 1 CD4 cell/μL (0 %), haemoglobin 9.8 g/dl, and normal renal and liver function tests.
Esophageal candidiasis and normocytic-normochromic anaemia were diagnosed. She received fluconazole,
prophylactic cotrimoxazole and tenofovir/emtricitabine/efavirenz. Seven weeks later she presented with
inflammatory skin plaques with elevated margins and central hyperpigmentation on the trunk, face and limbs in
the frame of a good general recovery and increased CD4 counts (188 cells/μL, 6 %). Tinea-IRIS was suspected and
treated with griseofulvin 500 mg daily and prednisolone 1 mg/Kg tapered down after 1 week, with total resolution
of symptoms in 2 weeks.
Conclusion: The two cases had advanced immunosuppression and developed de-novo exaggerated manifestation
of inflammatory lesions compatible with tinea corporis and tinea facies in temporal association with antiretroviral
treatment initiation and good immunological response. This is compatible with unmasking tinea-IRIS, and reminds
African clinicians about the importance of considering this entity in the differential diagnosis of patients with skin
lesions developing after antiretroviral treatment initiation.
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Background
Immune reconstitution inflammatory syndrome as-
ociated with dermatophytoses (tinea-IRIS) may cause
considerable morbidity given the high prevalence of fun-
gal skin infections, especially in HIV/AIDS patients with
late presentation. Despite having been reported to be
associated with 52–78 % of cutaneous associated IRIS
[1], it has been scarcely reported and is rarely considered
in the differential diagnosis of HIV-associated cutaneous
lesions in Sub-Saharan Africa (SSA). If identified, it
responds well to antifungals combined with steroids [2].
We present two photographically documented cases of
suspected tinea-IRIS in HIV-individuals in rural
Tanzania. The two patients developed the lesions two
and 7 weeks respectively after starting antiretroviral
treatment (ART). They were treated with fluconazole
and griseofulvin respectively combined with oral pred-
nisolone. The symptoms resolved after 8 and 2 weeks in
both patients respectively.
Case I presentation
A 33 years-old Tanzanian woman presented to the HIV
clinic suffering from skin itching for 3 months prior to
the visit. She tested positive for HIV and she was en-
rolled in care. At the baseline physical examination she
had pruritic papular eruptions (PPE) involving both
upper and lower limbs. Other systems and the vital signs
were unremarkable.
Investigations
Her baseline investigations showed CD4 count of 4
cells/μL (0 %), with normal complete blood count
(CBC), liver function test (LFT) and estimated glomeru-
lar filtration rate (eGFR). She had negative Cryptococcal
plasma antigen (CRAG) and Venereal Disease Research
Laboratory (VDRL) test. She also had negative Hepatitis
B surface antigen (HBsAg) and negative screening test
for cervical cancer screening.
Treatment
She was started ART on day four after enrollment into
care in our HIV-Clinic on co-formulated tenofovir
disoproxil fumarate 300 mg/emtricitabine 200 mg/efavir-
enz 600 mg (TDF/FTC/EFV) with prophylactic cotri-
moxazole, 960 mg once daily. She was also prescribed
symptomatic treatment for PPE, receiving cetirizine
5 mg once daily for 1 week.
Outcome and follow-Up
Two weeks after initiating ART she returned to the HIV-
clinic with an exaggerated inflammatory manifestation,
including hyperpigmented skin plaques with central
desquamation and active borders on the face, trunk and
lower limbs. The lesions were itching and surrounded by
scratchy lesions (Fig. 1). Tinea-IRIS was suspected and
fluconazole (150 mg daily), prednisolone (1 mg/kg for
1 weeks tapered down during the second week) and
cetirizine 5 mg once daily for 1 week were given. Her
symptoms subsided after 8 weeks of antifungal treatment
(Fig. 1). Her CD4 count after 2 months on ART increased
to 134 cells/μL (11 %) (Table 1).
Case II presentation
A 35 years-old newly HIV-diagnosed female presented to
the HIV clinic complaining of generalized body itching
associated with intermittent papular rashes involving both
lower limbs, which had started 1 month prior to the visit.
She also had difficult in swallowing and dry cough for 1
week. She reported experienced night sweats, weight loss
and chest pain for the last months. On physical examin-
ation she had oral thrush, PPE involving both lower limbs
and bronchial breath sounds on auscultation. Other
systems explorations were normal.
Investigations
Her baseline CD4 count was of 1 cell/μL (0 %). Her CBC
showed normocytic normochromic anemia (haemoglobin
Fig. 1 Pictures of the case I before and after treatment. Picture a shows exaggerated inflammatory manifestation, including hyperpigmented skin
plaques with central desquamation and active borders. The lesions were itching in nature surrounded by scratchy lesions on the face, trunk and
lower limbs. Picture b shows improvement after 8 weeks treatment with fluconazole, prednisolone and cetirizine
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9.8 g/dl, MCV 86 femtoliter, MCH 28 picograms/cell) with
an otherwise unremarkable CBC and normal LFT and
eGFR. She had negative CRAG, VDRL, HBsAg and cervical
cancer screening. Her chest radiograph showed alveolo-
interstitial opacities involving the left lower lobe and a
diagnosis of community acquired pneumonia (CAP) was
reached. Sputum smears were negative for Acid Fast Bacilli
and Xpert MTB/RIF on sputum was negative as well.
Treatment
She received fluconazole 150 mg once daily for 21 days
for oropharyngeal and suspected esophageal candidiasis,
amoxicillin 1 g three times daily during week one for
CAP, prophylaxis with cotrimoxazole 960 mg once daily
and 400 mg of ferric ammonium citrate / 3 mg of folic
acid daily for 1 month for anemia. She started ART 3
days later with TDF/FTC/EFV.
Outcome and follow-up
Seven weeks after ART initiation she started to experience
skin rashes in both upper limbs, which rapidly involved
the neck, trunk and the face (Fig. 2). The lesions clinically
progressed to inflammatory skin plaques with elevated
margins and central hyperpigmentation on the trunk, face
and limbs in the frame of a good general recovery and in-
creased CD4 count and percentage (188 cells/μL - 6 %).
Tinea-IRIS was suspected and treated with griseofulvin
500 mg once daily with prednisolone 1 mg/kg for 1 week
tapered down during the second week and cetirizine 5 mg
once daily for 1 week. At the end of the second week of
antifungal and steroid treatment, there was total reso-
lution of the lesions (Fig. 2) (Table 1).
Discussion
The occurrence of PPE in adult African patients has
been observed as highly predictive of HIV infection [3]
and has been correlated with low CD4+ cell count (<200
cells/l). Differential diagnosis of PPE includes tinea, a
fungal infection which involves the keratinized epidermis,
nails, and hair caused by common opportunistic patho-
gens associated with HIV.
No comprehensive studies on dermatophyte infections
have been conducted on HIV-individuals in low-income
countries (LIC), where more than 90 % of the global HIV-
infected population resides. Prevalence of tinea infestation
among people living with HIV (PLHIV) is likely to be high
and to occur in all HIV-infected patients at one point of
their lives [4]. Three types of dermatophytes account for
the majority of infections: Epidermophyton, Trichophyton,
and Microsporum. The most common dermatophytes
affecting PLHIV includes Trichophyton rubrum, which is
known to be the most prevalent, followed by Trichophyton
mentagrophytes, Trichophyton tonsurans, Candida albi-
cans, and Epidermophyton floccosum [5]. The infection in
PLHIV has been associated with the degree of immuno-
suppression, being more frequent with low CD4 count like
in our two patients. The clinical presentation range from
being asymptomatic to disseminated disease affecting all
four extremities.
Tinea, also known as ring worm, is the term repre-
senting a variety of skin mycoses and its diagnosis
could be confirmed by potassium hydroxide (KOH)
examination of scrapings from material taken from
the active border of the lesions. This is a very simple
laboratory examination which should be made widely
available in resource limited settings. A fungal culture
on Sabouraud’s medium can also be used to confirm
the diagnosis, although it is slower. Although the
etiological diagnosis relies on microbiological techniques,
in rural settings of LIC diagnosis is mostly based on
clinical judgment.
The availability of ART in SSA has significantly im-
proved the quality of life for PLHIV. However, despite the
fact that ART usually causes viral load suppression and
restores patient’s immunity, in some patients the restored
immune response is immunopathological and causes the
immune reconstitution inflammatory syndrome (IRIS) [6].
IRIS occurs when immunity is restored especially in the
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first months of effective ART. In a prospective cohort
study conducted among HIV patients in South Africa,
10.4 % of patients initiating ART developed IRIS [7].
Mucocutaneous manifestations of IRIS have been poorly
documented. A study conducted in Mozambique showed
26.5 % of patients developed IRIS after a median time of
62 days from ART initiation with 53 % of them having
mucocutaneous manifestations. Tinea accounted for 47 %
of all mucocutaneous IRIS cases [8]. In another study
conducted in Brazil, 10–25 % of unselected patients start-
ing ART developed IRIS with 52–78 % of these patients
presenting with cutaneous features [1, 9]. Tinea-IRIS le-
sions can be visible on patient’s skin, and despite not
being associated with mortality can cause a decrease in
the quality of life [10]. Moreover, it requires a high index
of suspicion to be treated.
In this report, we present two HIV infected patients
whom we suspected to develop tinea-IRIS after starting
ART. The first case developed tinea-IRIS 2 weeks after
starting ART and was successfully treated with flucona-
zole and prednisolone. The second case presented with
suspected tinea-IRIS 7 weeks after starting ART. With
the evidence of increase in resistance to fluconazole after
a prolonged exposure and the fact that she was treated
for esophageal candidiasis with fluconazole for 3 weeks,
she was treated with oral griseofulvin and prednisolone
and her symptoms subsided completely after 2 weeks of
treatment. Although highly suggestive of IRIS due to the
temporal association with ART initiation and the con-
comitant immune reconstitution, de novo dermatophyte
infection cannot be ruled out in this case [11]. We treated
both patients with two locally available antifungals which
have shown to be effective against tinea infection and can
be combined with steroids [2].
Conclusion
To our knowledge these are the first two cases with tinea-
IRIS to be reported in Tanzania. The two cases presented
had advanced immunosuppression and developed de-
novo exaggerated inflammatory lesions compatible with
tinea corporis and facies in temporal association with
ART initiation and good immunological response. This is
compatible with unmasking tinea-IRIS, and reminds
African clinicians about the importance of considering
this entity in the differential diagnosis of patients with skin
lesions developing after ART initiation, as fungal skin in-
festation is likely to be widely prevalent. Close follow-up is
warranted in late presenters to timely identify and treat
IRIS. In LIC like Tanzania where there are 4,993 estimated
cases of serious fungal infections per 100,000 person/year,
clinical judgment, appropriate microbiological tests and
laboratory trained technicians are vital [12]. Additionally,
since treatment with readily available in LIC antifungals
such as fluconazole and griseofulvin combined with predi-
nisolone have been proved to be effective, early diagnosis
and treatment is paramount to reduce the associated mor-
bidity, as shown by these two cases.
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